Effect of phenytoin on the clinical signs and in vitro muscle twitch characteristics in horses with chronic intermittent rhabdomyolysis and myotonia.
In vitro twitch characteristics of the semimembranosus muscle were evaluated in 9 clinically normal horses, in 15 horses with chronic intermittent rhabdomyolysis (CIR) and in 2 horses with myotonia. Effects of phenytoin on in vitro muscle twitch and clinical signs of CIR and myotonia were evaluated in these same horses. Times to 90% relaxation were prolonged in the horses with CIR (mean +/- SEM, 186 +/- 5.9 ms) and in 2 horses with myotonia (197 and 177 ms) compared with those in clinically normal horses (mean +/- SEM, 146 +/- 2.1 ms). Horses with CIR also had significantly (P less than 0.05) longer times to 50% relaxation, compared with clinically normal horses. In the group of horses with CIR, Standardbreds had significantly (P less than 0.05) longer times to 90% and 50% relaxation, compared with Thoroughbreds. Times to 100% peak tension did not differ among the groups. Administration of phenytoin directly into a muscle preparation bath solution had no effect on muscle twitch properties. After the initial muscle biopsy, phenytoin was administered orally for 7 to 10 days to 4 horses with CIR, 2 myotonic horses, and 2 clinically normal horses before repeat biopsy from the same site in the contralateral semimembranosus muscle. Times to 90% relaxation decreased from 197 and 177 ms to 144 and 126 ms, respectively, in the 2 myotonic horses, from a mean of 192 (+/- 9) ms to 170 (+/- 9) ms in the 4 horses with CIR and remained unchanged (154 and 140 ms before vs 155 and 139 ms after treatment) in the 2 clinically normal horses.(ABSTRACT TRUNCATED AT 250 WORDS)
Beech
J
J
Section of Medicine, School of Veterinary Medicine, University of Pennsylvania, New Bolton Center, Kennett Square 19348.
Fletcher
J E
JE
Lizzo
F
F
Johnston
J
J
D000284:Administration, Oral; D000818:Animals; D002908:Chronic Disease; D003402:Creatine Kinase / Q000032:analysis; D005260:Female; D005684:Gait; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses / Q000097:blood / Q000502:physiology*; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D009222:Myotonia / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary*; D010672:Phenytoin / Q000008:administration & dosage / Q000627:therapeutic use*; D012206:Rhabdomyolysis / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary*
D010672:Phenytoin; D003402:Creatine Kinase